• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

Baseball-style Stats for Radiologists

Article

Whatever the reason, when I got my performance report for last quarter’s radiology work, I found myself musing about the stats used to measure us.

Perhaps it’s because I’ve got baseball’s spring training on my mind, or I’ve still got a jumble of worthless football-related statistics rattling around in my head from last season. Whatever the reason, when I got my performance report for last quarter’s radiology work, I found myself musing about the stats used to measure us. 

Accuracy rates, turnaround time, work volume - plenty of ways to stratify your radiologists. Or at least to rattle their cages and see who gets the most neurotic.

It occurred to me that in radiology, we’re incomplete with our statistics. All of our numbers pertain to the imaging department’s side of things. This is sort of like focusing on a baseball pitcher’s ERA without considering the batters he’s facing. Our batters, therefore, would be the clinicians who send us our cases. (You can make the clinicians the pitchers and us the batters if you prefer.) I think we’re missing out on a lot of 360-degree-review types of valuable feedback by not tracking their statistics along with our own.

To start, we could have a true-positive percentage (TPP), analogous to a batting average. Simply put, what percentage of imaging studies sent by a given clinician yields an abnormality? A nurse in the ER who ordered a gazillion abdominal CTs but only turned up pathology one time in 20, for instance, would have a TPP of .050. A seasoned diagnostician who only sent patients for imaging when he had a high index of suspicion, whose studies were abnormal one time in three, would have a TPP of .333 - a respectable number even for a major-leaguer.

For any who may take this too seriously, and worry that clinicians would be tempted to game the system and refrain from imaging patients to beef up their TPP (only sending rip-roaring sick patients for imaging and withholding studies from others, potentially missing pathology as a result), we could have a false-negative percentage (FNP).

Of greater interest and potential fun would be a stat analogous to baseball’s slugging percentage. Let’s call it the Clinical Prowess Quotient, or CPQ. For those unfamiliar, the slugging percentage is a measurement of not only how frequently one hits the ball, but how powerfully/effectively he does so.

Similarly, the CPQ would measure how accurately the provided clinical history for imaging matched the actual diagnosis. A history of “R/O Pathology” or “Pain” would be a zero, no matter what the study showed. On the other hand, a clinical history of “Acute appendicitis” for a scan that, indeed, showed an appy, would get 100 percent (batting 1.000, in baseball terms). The same patient, with a history of “right lower quadrant pain,” might yield a CPQ of .333; At least the clinician was accurate in terms of where the pathology was.

Understandably, some of these stats would have subjective elements. Then again, our own metrics in radiology aren’t free of such imperfection. One man’s “agree with original interpretation” is another’s “subtle discrepancy.” Heck, even the major leagues experience controversial disputes as to what was or was not a fielding error.

I’m sure that some of our clinical colleagues would bridle at being graded by us, directly or indirectly. Heck, I don’t think that many of us relish the feeling of being constantly watched and reassessed, but telling them that “turnabout is fair play” probably wouldn’t smooth any ruffled feathers. We might get better traction from the promise of bragging rights, or even a new set of credentials to flaunt on the job market: “Hey, we should really try to recruit Dr. X. I hear his CPQ is over .500!” Who knows, Vegas might start offering bets on this stuff.

Recent Videos
Radiology Study Finds Increasing Rates of Non-Physician Practitioner Image Interpretation in Office Settings
Assessing a Landmark Change in CMS Reimbursement for Diagnostic Radiopharmaceuticals
Addressing the Early Impact of National Breast Density Notification for Mammography Reports
2 KOLs are featured in this series.
2 KOLs are featured in this series.
Can 18F-Floutufolastat Bolster Detection of PCa Recurrence in Patients with Low PSA Levels After Radical Prostatectomy?
2 KOLs are featured in this series.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
Related Content
© 2024 MJH Life Sciences

All rights reserved.